Cargando…
Spot urinary microalbumin concentration, metabolic syndrome and type 2 diabetes: Tehran lipid and glucose study
AIM: This study aimed to determine the association of urinary microalbumin concentrations with type 2 diabetes mellitus (T2DM), metabolic syndrome (MetS), and its phenotypes. The optimum cut-off values of urinary microalbumin and microalbumin-to-creatinine ratio (MCR) for predicting the chance of ha...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905801/ https://www.ncbi.nlm.nih.gov/pubmed/35260113 http://dx.doi.org/10.1186/s12902-022-00976-x |
_version_ | 1784665269611790336 |
---|---|
author | Gaeini, Zahra Bahadoran, Zahra Mirmiran, Parvin Norouzirad, Reza Ghasemi, Asghar Azizi, Fereidoun |
author_facet | Gaeini, Zahra Bahadoran, Zahra Mirmiran, Parvin Norouzirad, Reza Ghasemi, Asghar Azizi, Fereidoun |
author_sort | Gaeini, Zahra |
collection | PubMed |
description | AIM: This study aimed to determine the association of urinary microalbumin concentrations with type 2 diabetes mellitus (T2DM), metabolic syndrome (MetS), and its phenotypes. The optimum cut-off values of urinary microalbumin and microalbumin-to-creatinine ratio (MCR) for predicting the chance of having T2DM and MetS were also defined. METHODS: Adult men and women (n = 1192) participated in the sixth phase (2014-2017) of the Tehran Lipid and Glucose Study (TLGS), with completed data, were included in the analyses. Odds ratios (ORs) (and 95% confidence intervals (CIs)) of T2DM, MetS, and its components across tertile categories of urinary microalbumin concentrations were estimated using multivariable logistic regressions. The optimal cut-off points of urinary microalbumin and MCR were determined using the receiver operator characteristic (ROC) curve analysis. RESULTS: Participants’ mean (±SD) age was 44.9 (±14.0) years, and 44.6% of the participants were men. The prevalence of microalbuminuria was 14.4%. Chance of having T2DM was significantly higher in the highest tertile of urinary microalbumin concentration (OR = 2.29, 95% CI = 1.43-3.67) and MCR (OR = 1.82, 95% CI = 1.15-2.89). Subjects with the highest urinary microalbumin concentration were more likely to have MetS (OR = 1.66, 95% CI = 1.17-2.35), hypertension (OR = 1.63, 95% CI = 1.16-2.30) and hyperglycemia (OR = 1.78, 95% CI = 1.24-2.56). No significant association was observed between urinary microalbumin concentrations and other components of MetS. The optimal cut-off points of urinary microalbumin for predicting the chance of having T2DM and MetS were 14.0 and 13.6 mg/L, respectively. CONCLUSIONS: Elevated spot urinary microalbumin, below the values defined as microalbuminuria, was associated with the chance of having T2DM and MetS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12902-022-00976-x. |
format | Online Article Text |
id | pubmed-8905801 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-89058012022-03-18 Spot urinary microalbumin concentration, metabolic syndrome and type 2 diabetes: Tehran lipid and glucose study Gaeini, Zahra Bahadoran, Zahra Mirmiran, Parvin Norouzirad, Reza Ghasemi, Asghar Azizi, Fereidoun BMC Endocr Disord Research AIM: This study aimed to determine the association of urinary microalbumin concentrations with type 2 diabetes mellitus (T2DM), metabolic syndrome (MetS), and its phenotypes. The optimum cut-off values of urinary microalbumin and microalbumin-to-creatinine ratio (MCR) for predicting the chance of having T2DM and MetS were also defined. METHODS: Adult men and women (n = 1192) participated in the sixth phase (2014-2017) of the Tehran Lipid and Glucose Study (TLGS), with completed data, were included in the analyses. Odds ratios (ORs) (and 95% confidence intervals (CIs)) of T2DM, MetS, and its components across tertile categories of urinary microalbumin concentrations were estimated using multivariable logistic regressions. The optimal cut-off points of urinary microalbumin and MCR were determined using the receiver operator characteristic (ROC) curve analysis. RESULTS: Participants’ mean (±SD) age was 44.9 (±14.0) years, and 44.6% of the participants were men. The prevalence of microalbuminuria was 14.4%. Chance of having T2DM was significantly higher in the highest tertile of urinary microalbumin concentration (OR = 2.29, 95% CI = 1.43-3.67) and MCR (OR = 1.82, 95% CI = 1.15-2.89). Subjects with the highest urinary microalbumin concentration were more likely to have MetS (OR = 1.66, 95% CI = 1.17-2.35), hypertension (OR = 1.63, 95% CI = 1.16-2.30) and hyperglycemia (OR = 1.78, 95% CI = 1.24-2.56). No significant association was observed between urinary microalbumin concentrations and other components of MetS. The optimal cut-off points of urinary microalbumin for predicting the chance of having T2DM and MetS were 14.0 and 13.6 mg/L, respectively. CONCLUSIONS: Elevated spot urinary microalbumin, below the values defined as microalbuminuria, was associated with the chance of having T2DM and MetS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12902-022-00976-x. BioMed Central 2022-03-08 /pmc/articles/PMC8905801/ /pubmed/35260113 http://dx.doi.org/10.1186/s12902-022-00976-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Gaeini, Zahra Bahadoran, Zahra Mirmiran, Parvin Norouzirad, Reza Ghasemi, Asghar Azizi, Fereidoun Spot urinary microalbumin concentration, metabolic syndrome and type 2 diabetes: Tehran lipid and glucose study |
title | Spot urinary microalbumin concentration, metabolic syndrome and type 2 diabetes: Tehran lipid and glucose study |
title_full | Spot urinary microalbumin concentration, metabolic syndrome and type 2 diabetes: Tehran lipid and glucose study |
title_fullStr | Spot urinary microalbumin concentration, metabolic syndrome and type 2 diabetes: Tehran lipid and glucose study |
title_full_unstemmed | Spot urinary microalbumin concentration, metabolic syndrome and type 2 diabetes: Tehran lipid and glucose study |
title_short | Spot urinary microalbumin concentration, metabolic syndrome and type 2 diabetes: Tehran lipid and glucose study |
title_sort | spot urinary microalbumin concentration, metabolic syndrome and type 2 diabetes: tehran lipid and glucose study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905801/ https://www.ncbi.nlm.nih.gov/pubmed/35260113 http://dx.doi.org/10.1186/s12902-022-00976-x |
work_keys_str_mv | AT gaeinizahra spoturinarymicroalbuminconcentrationmetabolicsyndromeandtype2diabetestehranlipidandglucosestudy AT bahadoranzahra spoturinarymicroalbuminconcentrationmetabolicsyndromeandtype2diabetestehranlipidandglucosestudy AT mirmiranparvin spoturinarymicroalbuminconcentrationmetabolicsyndromeandtype2diabetestehranlipidandglucosestudy AT norouziradreza spoturinarymicroalbuminconcentrationmetabolicsyndromeandtype2diabetestehranlipidandglucosestudy AT ghasemiasghar spoturinarymicroalbuminconcentrationmetabolicsyndromeandtype2diabetestehranlipidandglucosestudy AT azizifereidoun spoturinarymicroalbuminconcentrationmetabolicsyndromeandtype2diabetestehranlipidandglucosestudy |